926 Immune profiling of KEAP1-deficient NSCLC: development of therapeutic strategies to overcome resistance to immunotherapy

• Linghua Wang,
• Alexandre Reuben,
• John Heymach,
• Xiang Zhang,
• Ignacio Wistuba,
• Ferdinandos Skoulidis,
• Edwin Parra,
• Minghao Dang,
• Yu Qian,
• Daniel McGrail,
• Ana Galan-Cobo,
• Fuduan Peng,
• Fahao Zhang,
• Saxon Rodriguez

Affiliations

Linghua Wang

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Alexandre Reuben

Aff1 grid.240145.60000000122914776Surgical OncologyMD Anderson Cancer Center Houston TX USA

John Heymach

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Xiang Zhang

Institute of Digestive Disease and The Department of Medicine and Therapeutics,State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences,CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China SAR

Ignacio Wistuba

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Ferdinandos Skoulidis

Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Edwin Parra

1MD Anderson Cancer Center, Houston, TX, USA

Minghao Dang

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Yu Qian

Diseases & Population (DaP) Geninfo Lab, School of Lifesciences, Westlake University, Hangzhou, Zhejiang, China

Daniel McGrail

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ana Galan-Cobo

UT MD Anderson Cancer Center, Houston, TX, USA

Fuduan Peng

UT MD Anderson Cancer Center, Houston, TX, USA

Fahao Zhang

UT MD Anderson Cancer Center, Houston, TX, USA

Saxon Rodriguez

UT MD Anderson Cancer Center, Houston, TX, USA